The company already leases space in Bothell. The press announcement says the company will be expanding into 27,000 sf in Bothell beginning in June and continuing through the end of the year. The facility will include manufacturing capacity for up to 50 million dosage units per year, a significant increase over current capacity.
The company's communications director Matthew D. Haines, who will not be making the move, did not know where the company is currently located in Bothell, where the new space is located or who owns either building. Quay's was unavailable for comment.
"Nastech is on a growth trajectory that requires additional staff, laboratory, and manufacturing capacity," stated Quay in the press release. "The Seattle, Washington area is an evolving biotechnology hub with a tremendous pool of scientific talent, which will further expand our R&D activities."
Nastech currently occupies 38,000 sf of research and manufacturing space in Hauppauge, New York, where the company manufactures Nascobal(R), its FDA approved vitamin B-12 nasal gel. Nastech will maintain certain R&D activities at its Hauppauge site, and also is adding manufacturing capacity there for up to 5 million dosage units per year.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
